

Telephone: General Lines: 256 - 417-712260
Permanent Secretary's Office: 256 -417- 712221
Toll Free 0800100066

E-mail : ps@health.go.ug
Website: www.health.go.ug

IN ANY CORRESPONDENCE ON
THIS SUBJECT PLEASE QUOTE NO

ADM.214/283/01



THE REPUBLIC OF UGANDA

Ministry of Health
P. O. Box 7272
Plot 6, Lourdel Road
KAMPALA
UGANDA

2nd November 2020

The Director,
Uganda Virus Research Institute
ENTEBBE

DESIGNATION AS SARS-Cov-2 COVID-19 NATIONAL DIAGNOSTIC REFERENCE LABORATORY.

As part of the National Response for COVID-19 Public Health Emergency, I am pleased on behalf of the Ministry of Health (MOH) to designate Uganda Virus Research Institute (UVRI) as the Uganda SARS-Cov-2/COVID-19 National Diagnostic Reference Laboratory. The designation is based on the historical role and expertise played by UVRI in previous outbreaks of viral infections in Uganda and acknowledgement of UVRI by national and international partners in responding to several outbreaks associated with viral infections including viral hemorrhagic fevers over several years.

In accordance with this role, UVRI as a National Reference lab is expected to provide leadership in building and supporting the necessary laboratory and diagnostic capacity for adequate detection of and response to COVID-19 for the country. This role will be periodically reviewed by MOH with a view to ensuring UVRI's optimum effectiveness in providing the anticipated leadership particularly for supporting efficient response to COVID19.


In performance of this role, UVRI will be guided by the following Terms of Reference as the COVID-19 Reference Laboratory:

Uganda Virus Research Institute (UVRI) will:

1. Provide COVID-19-related virological expertise and laboratory support, including training, to all national COVID testing laboratories
2. Support capacity building of COVID-19 testing laboratories in the country including supporting decentralization of COVID-19 testing to optimize the capacity across the country in collaboration with CPHL

A handwritten signature in black ink, appearing to read 'J. M. Mwach', written over a horizontal line.

3. Develop and implement state-of-the art methods for COVID-19 testing
4. Act as the national center for validation of COVID-19 diagnostic assays before they are licensed for use in the country and provide to MOH and relevant government agencies, technical details of diagnostic assays developed and/or evaluated by UVRI for the detection of COVID-19 virus;
5. Provide a national reference resource of well-characterized proficiency panels and materials for ensuring quality assurance for COVID-testing in the country
6. Characterize viruses including through whole genome sequencing and provide such sequence data to a publicly-accessible data base; and provide MOH updates of the evolution of the virus and its relevant to epidemic response
7. Track the evolution of the virus causing COVID-19 and identify changes that may be relevant to diagnostic tests, vaccine development and/or antiviral treatment;
8. Depending on the further evolution of the COVID-19 epidemic, provide technical guidance towards
 - i. development or refinement of diagnostic assays
 - ii. development of protocols for antiviral resistance testing;
 - iii. antigenic characterization of the circulating SARS-CoV-2 viruses;
 - iv. development/assessment of specific tests for diagnostic humoral immune responses; and
 - v. development of tests for infectivity of recovering patients.
9. To the best of your capacity and through harnessing other diagnostic capabilities in the country, provide confirmatory testing of virus materials and other clinical samples from suspected cases of COVID-19
10. Support improvement of biosafety procedures across all testing facilities
11. Working with other partners and MOH, support the development and maintenance of an updated SARS-Cov-2/COVID-19 testing algorithm for the country

A handwritten signature in black ink, appearing to read 'J. W. Mwach', is located at the bottom center of the page.

been established with the Provider covering such other use; any such separate agreement will be provided to MOH.


19. UVRI shall ensure that results of the use of the materials for the Purpose are only reported to MOH or other labs that provided the materials (hereinafter, the Provider")

20. UVRI will, subject to agreement with MOH and/or Provider, as applicable, be entitled to publish the results of the use of the materials for the Purpose;

21. Adhere to and comply with:

- i. all applicable laws, statutes, rules, regulations and other legal or ethical requirements;
- ii. all relevant national and/or international biosafety standards for work with high-threat pathogens; and
- iii. all national and international regulations relating to the receipt of dangerous goods;

22. Obtain and maintain in effect any applicable national and/or international licenses, permits, authorizations, accreditations, documentation and/or other recognition which are necessary or required for the laboratory to perform its tasks



Dr. Henry G. Mwebesa
DIRECTOR GENERAL HEALTH SERVICES

- cc. Hon. Minister of Health
Hon. Minister of State for Health (GD)
Hon. Minister of State for Health (PHC)
Permanent Secretary
WHO Country Representative
CDC Country Director
Directors / MOH
The Incident Commander COVID-19
Commissioner Laboratory and Diagnostic Services